Immediate improvements in glycaemic control associated with MiniMed 780G system

Glycaemic control improved immediately after using the MiniMed 780G system and remained stable over three years.

This is according to research presented at this year’s annual meeting of The European Association for the Study of Diabetes (EASD) in Vienna.

During the trial, the team of researchers evaluated the glycaemic control, user burden and system trust among real-world users of the MiniMed 780G system in Europe, the Middle East and the Africa (EMEA) region over a three-year follow-up period.

They found that the MiniMed 780G system increased TIR to 78.6 per cent and TITR to 53.7 per cent, with them both remaining stable over three years.

In addition, they discovered that user burden decreased immediately after use of the MiniMed 780G system, with user-delivered insulin falling from 52.4 per cent to 41.5 per cent.

The number of user-initiated boluses fell from 5.6 to 4.8 per day, according to the research results.

System trust, as reflected by the percentage of users on optimal setting, also increased over time, with 55 per cent of users recommending optimal settings by the end of the study.

Lead author Jen McVean said: “As we approach the era of fully closed-loop AID, trust in and reliance upon the AID system are critical for success.”

A separate study, also presented at EASD 2025, concluded that the MiniMed 780G system demonstrated sustained safety and effective glycaemic control for at least one year in users aged two to six years with a TDD>6U.